Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
In Reply: Dr Potyk raises the interesting question
of what is gained by secondary publications from large trials after the main
article has been published. First, the main report of a trial is generally
too concise to include all the important information. Second, some information
(usually secondary outcomes) may be mentioned very briefly (eg, 1 line regarding
prevention of diabetes with ramipril in our original article) so that the
information is either missed by readers or is not provided in adequate detail
for careful evaluation.1 Third, some data
are of interest to some parts of the scientific community and not to others.
As an example, in HOPE there was substantial benefit with ramipril among those
with peripheral arterial disease. Hence a detailed and separate report would
be necessary. Fourth, substudies that focus on specific outcomes not included
in the primary report (eg, carotid atherosclerosis,2
left ventricular hypertrophy, renal disease progression) require separate
publication. Fifth, new observational analysis (eg, the prediction of events
by even small increases in urinary microalbumin excretion) deserve public
dissemination.3 We believe that an enormous
amount of useful knowledge can be derived from large carefully conducted studies
through judicious publications and that full dissemination of these results
is likely to be helpful to the scientific community.
Yusuf S. Ramipril and Risk of Diabetes—Reply. JAMA. 2002;287(2):186-187. doi:10.1001/jama.287.2.186